MK-4305

OX1/OX2 atagonist,potent and selective CAS# 1030377-33-3

MK-4305

Catalog No. BCC1760----Order now to get a substantial discount!

Product Name & Size Price Stock
MK-4305: 5mg $81 In Stock
MK-4305: 10mg Please Inquire In Stock
MK-4305: 20mg Please Inquire Please Inquire
MK-4305: 50mg Please Inquire Please Inquire
MK-4305: 100mg Please Inquire Please Inquire
MK-4305: 200mg Please Inquire Please Inquire
MK-4305: 500mg Please Inquire Please Inquire
MK-4305: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of MK-4305

Number of papers citing our products

Chemical structure

MK-4305

3D structure

Chemical Properties of MK-4305

Cas No. 1030377-33-3 SDF Download SDF
PubChem ID 24965990 Appearance Powder
Formula C23H23ClN6O2 M.Wt 450.92
Type of Compound N/A Storage Desiccate at -20°C
Solubility Limited solubility
Chemical Name [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone
SMILES CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl
Standard InChIKey JYTNQNCOQXFQPK-MRXNPFEDSA-N
Standard InChI InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of MK-4305

DescriptionMK-4305 is a potent antagonist of OX1 receptor and OX2 receptor with Ki values of 0.55 nM and 0.35 nM, respectively.
TargetsOX1 receptorOX2 receptor    
IC500.55 nM0.35 nM    

MK-4305 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

MK-4305 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of MK-4305

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.2177 mL 11.0884 mL 22.1769 mL 44.3538 mL 55.4422 mL
5 mM 0.4435 mL 2.2177 mL 4.4354 mL 8.8708 mL 11.0884 mL
10 mM 0.2218 mL 1.1088 mL 2.2177 mL 4.4354 mL 5.5442 mL
50 mM 0.0444 mL 0.2218 mL 0.4435 mL 0.8871 mL 1.1088 mL
100 mM 0.0222 mL 0.1109 mL 0.2218 mL 0.4435 mL 0.5544 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on MK-4305

MK-4305 (Suvorexant)
Description:
Ki: MK-4305 is a potent antagonist of OX1 receptor and OX2 receptor with Ki values of 0.55 nM and 0.35 nM, respectively [1].
Orexins/hypocretins are key neuropeptides responsible for regulating central arousal and reward circuits. Two receptors respond to orexin signaling, orexin 1 receptor (OX1R) and orexin 2 receptor (OX2R) with partially overlapping nervous system distributions. As a dual orexin receptor (OXR) antagonist (DORA), suvorexant (MK-4305) has shown promise for the treatmen to finsomnias and sleep disorders.
In vitro: In vitro study showed that MK-4305 possesseed a clean ancillary profile (>10000-fold selectivity for OX2R) as determined by an MDS Pharma off-target screen of 170 enzymes, receptors, and ion channels [1].
In vivo: In a mice in-vivo study, suvorexant (25mg/kg) was tested in mice during the inactive phase (lights on) when sleep is naturally more prevalent and when orexin levels are normally low. It was found that suvorexant substantially disturbed the sleep architecture by selectively increasing REM during the first 4h after dosing. At the doses tested, suvorexant significantly decreased wake only during the first hour and IPSU did not affect wake time. These data suggest that OX2R preferring antagonists may have areduced tendency for perturbing NREM/REM architecture in comparison with DORAs [2].
Clinical trial: Suvorexant (trade name Belsomra) is marketed by Merck & Co. for the treatment of insomnia. It is effective for insomnia, at least for four weeks and as compared to a placebo. It was approved for sale by the U.S. Food & Drug Administration on August 13, 2014. The United States DEA has placed it on the list of schedule IV controlled substances. The drug became available in the United States on Tuesday, 3 February 2015 and Japan somewhere in November 2014 (http://en .wikipedia.org/wiki/Suvorexant).
Reference:
[1] Cox CD, Breslin MJ, Whitman DB, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem. 2010;53(14):5320-32.
[2] Hoyer D, Dürst T, Fendt M, Jacobson LH, Betschart C, Hintermann S, Behnke D, Cotesta S, Laue G, Ofner S, Legangneux E, Gee CE. Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front Neurosci. 2013;7:235.

Featured Products
New Products
 

References on MK-4305

Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual Orexin inhibitor Suvorexant (MK-4305).[Pubmed:21528938]

J Am Chem Soc. 2011 Jun 1;133(21):8362-71.

The first example of an intramolecular asymmetric reductive amination of a dialkyl ketone with an aliphatic amine has been developed for the synthesis of Suvorexant (MK-4305), a potent dual Orexin antagonist under development for the treatment of sleep disorders. This challenging transformation is mediated by a novel Ru-based transfer hydrogenation catalyst that provides the desired diazepane ring in 97% yield and 94.5% ee. Mechanistic studies have revealed that CO(2), produced as a necessary byproduct of this transfer hydrogenation reaction, has pronounced effects on the efficiency of the Ru catalyst, the form of the amine product, and the kinetics of the transformation. A simple kinetic model explains how product inhibition by CO(2) leads to overall first-order kinetics, but yields an apparent zero-order dependence on initial substrate concentration. The deleterious effects of CO(2) on reaction rates and product isolation can be overcome by purging CO(2) from the system. Moreover, the rate of ketone hydrogenation can be greatly accelerated by purging of CO(2) or trapping with nucleophilic secondary amines.

Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.[Pubmed:20565075]

J Med Chem. 2010 Jul 22;53(14):5320-32.

Despite increased understanding of the biological basis for sleep control in the brain, few novel mechanisms for the treatment of insomnia have been identified in recent years. One notable exception is inhibition of the excitatory neuropeptides orexins A and B by design of orexin receptor antagonists. Herein, we describe how efforts to understand the origin of poor oral pharmacokinetics in a leading HTS-derived diazepane orexin receptor antagonist led to the identification of compound 10 with a 7-methyl substitution on the diazepane core. Though 10 displayed good potency, improved pharmacokinetics, and excellent in vivo efficacy, it formed reactive metabolites in microsomal incubations. A mechanistic hypothesis coupled with an in vitro assay to assess bioactivation led to replacement of the fluoroquinazoline ring of 10 with a chlorobenzoxazole to provide 3 (MK-4305), a potent dual orexin receptor antagonist that is currently being tested in phase III clinical trials for the treatment of primary insomnia.

Keywords:

MK-4305,1030377-33-3,Natural Products,OX Receptor, buy MK-4305 , MK-4305 supplier , purchase MK-4305 , MK-4305 cost , MK-4305 manufacturer , order MK-4305 , high purity MK-4305

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: